Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. A total of 238 women with breast cancer before age 50 or ovarian cancer at any age and at ...
They are genes commonly associated with breast cancer in women, but in fact men who carry certain mutations in their BRCA1 or BRCA2 genes are at higher risk of developing certain types of cancer ...
6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or ...
Investigators evaluated the association between risk-reducing bilateral mastectomy and overall and breast cancer–specific mortality in female carriers of BRCA pathogenic variants.
In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.
Carriers of the BRCA1 cancer gene had a significantly increased risk of breast cancer if they used hormonal contraception (HC), pooled cohort data showed. Breast cancer risk increased by 29% in BRCA1 ...
A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, "Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the ...
Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, ...
More and more studies show that men face risks of cancer from BRCA1 and BRCA2 genetic mutations that are most often associated with breast and ovarian cancers in women. According to a July 25 JAMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results